Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

Rana R. McKay, MD
Published: Monday, Apr 16, 2018



Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).
SELECTED
LANGUAGE


Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x